Publications by authors named "Teresa Gantes Padrao"
Article Synopsis
- - The KEYNOTE-522 trial demonstrated that adding pembrolizumab to standard chemotherapy improves outcomes in patients with early triple negative breast cancer (TNBC), prompting a study to evaluate similar outcomes without this drug in a high-quality care setting.
- - A retrospective analysis of 168 untreated stage II or III TNBC patients receiving chemotherapy from 2012 to 2022 found a 52.7% rate of pathological complete response (pCR) and event-free survival (EFS) of 83.3% at 36 months.
- - Results suggest that specialized care in a certified Breast Unit can achieve outcomes comparable to those seen with the addition of pembrolizumab, indicating the importance of quality care in cancer treatment.
Unlabelled: Inferior vena cava syndrome is rare and often difficult to diagnose because of its rarity and consequent low suspicion. We describe the case of a 28-year-old female patient with a history of nephroblastoma of the right kidney, stage IV, with a favourable histology with epidural metastasis (D5-D9), diagnosed at 3 years of age. The patient underwent treatment with surgery, chemotherapy and radiotherapy.
View Article and Find Full Text PDF